Review of bosentan in the management of pulmonary arterial hypertension

References

• ASTP, ATS, ERS, ISHLT joint statementInternational guidelines for the selection of lung transplant patientsAm J Respir Crit Care Med199815833599655748
   PubMed Web of Science ®Google Scholar
• BarstRJIvyDDingemanseJPharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertensionClin Pharmacol Ther2003733728212709727
   PubMed Web of Science ®Google Scholar
• BarstRJRubinLJLongWAA comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study GroupN Engl J Med19963342963028532025
   PubMed Web of Science ®Google Scholar
• BenedictNJSitaxsentan in the management of pulmonary arterial hypertensionAm J Health-System Pharmacy2007643638
   PubMed Web of Science ®Google Scholar
• BenigniARamuzziGEndothelin antagonistsLancet1999353133810023915
   PubMed Web of Science ®Google Scholar
• BlackCPulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition?Rheumatology (Oxford)200544141215681336
   PubMed Web of Science ®Google Scholar
• BondermanDNowotnyRSkoro-SajerNBosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary HypertensionChest2005128259960316236930
   PubMed Web of Science ®Google Scholar
• BresserPFedulloPFAugerWRContinuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertensionEur Respir J20042359560015083760
   PubMed Web of Science ®Google Scholar
• ChannickRNSimonneauGSitbonOEffects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet200135811192311597664
   PubMed Web of Science ®Google Scholar
• ClozelMGrayGABreuVThe endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivoBiochem Biophys Res Commun1992186867731323294
   PubMed Web of Science ®Google Scholar
• D’AlonzoGEBarstRJAyresSM1991Survival in patients with primary pulmonary hypertension. Results from a national prospective registryAnn Intern Med11534391863023
   PubMed Web of Science ®Google Scholar
• DentonCPHumbertMRubinLBosentan therapy for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensionsAnn Rheum Dis20066513364016793845
   PubMed Web of Science ®Google Scholar
• DoyleRLMcCroryDChannickRNJournal of American College of Chest Physicians: Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelinesChest20041261S63S71S15249495
   PubMedGoogle Scholar
• FarberHWLoscalzoJPulmonary arterial hypertensionN Engl J Med200435116556515483284
   PubMed Web of Science ®Google Scholar
• FilepJGFournierAFoldes-FilepEAcute pro-inflammatory actions of endothelin-1 in the guinea pig lung: Involvement of ETA and ETB receptorsBr J Pharmacol1995115227367670725
   PubMed Web of Science ®Google Scholar
• FusterVSteelePMEdwardsWDPrimary pulmonary hypertension: natural history and the importance of thrombosisCirculation19847058076148159
   PubMed Web of Science ®Google Scholar
• GabbayEMcNeilKWilliamsTJBosentan for pulmonary arterial hypertension; the relationship between 6MWT and quality of lifeAm J Resp Crit Care Med2005169A175
   Google Scholar
• GaineSPRubinLJPrimary pulmonary hypertensionLancet1998352719259729004
   PubMed Web of Science ®Google Scholar
• GalieNGuidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of CardiologyEur Heart J20042522437815589643
   PubMed Web of Science ®Google Scholar
• GalieNBeghettiMGatzoulisMABosentan therapy in patients with Eisenmenger syndromeCirculation2006114485416801459
   PubMed Web of Science ®Google Scholar
• GalieNGhofraniHATorbickiASildenafil citrate therapy for pulmonary arterial hypertensionN Engl J Med200535321485716291984
   PubMed Web of Science ®Google Scholar
• GalieNGrigioniFBacchi-RggianinKRelation of endothelin-1 to survival in patients with primary pulmonary hypertensionEur J Clin Invest199626273
   Web of Science ®Google Scholar
• GalieNHinderliterALTorbickiAEffects of the oral endothelin-receptor antagonist Bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertensionJ Am Coll Cardiol2003411380612706935
   PubMed Web of Science ®Google Scholar
• GalieNSeegerWNaeijeRComparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertensionJ Am Coll Cardiol20044381S88S15194183
   PubMed Web of Science ®Google Scholar
• GiaidAYanagisawaMLanglebenDExpression of Endothelin-1 in the lungs of patients with pulmonary hypertensionN Engl J Med1993328173298497283
   PubMed Web of Science ®Google Scholar
• GirgisREMathaiSCKrishnanJALong-Term outcome of Bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseasesJ Heart Lung Transplantation200524162631
   PubMed Web of Science ®Google Scholar
• HoeperMMPulmonary hypertension in collagen vascular diseaseEur Respir J200219571611936539
   PubMed Web of Science ®Google Scholar
• HoeperMMDinh-XuanATCombination therapy for pulmonary arterial hypertension: still more questions than answersEur Respir J2004243394015358685
   PubMed Web of Science ®Google Scholar
• HoeperMMFaulenbachCGolponHCombination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertensionEur Respir J20042410071015572546
   PubMed Web of Science ®Google Scholar
• HoeperMMKielyDGCarlsenJSafety profile of pulmonary arterial hypertension patients treated with bosentan and sildenafil: results from the European surveillance programAm J Resp Crit Care Med2005169A135
   Google Scholar
• HoeperMMKrammTWilkensHBosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary HypertensionChest20051282363716236895
   PubMed Web of Science ®Google Scholar
• HoeperMMMarkevychISpierkerkoetterEGoal-oriented treatment and combination therapy for pulmonary arterial hypertensionEur Respir J2005268586316264047
   PubMed Web of Science ®Google Scholar
• HughesRGeorgePParameshwarJBosentan in inoperable chronic thromboembolic pulmonary hypertensionThorax20056070716061720
   PubMed Web of Science ®Google Scholar
• HughesRJJaisXBondermanDBosentan in inoperable chronic thromboembolic pulmonary hypertension: efficacy at 1 yearEur Respir J2006281384316611652
   PubMed Web of Science ®Google Scholar
• HumbertMBarstRJRobbinsIMCombination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2Eur Respir J200424353915358690
   PubMed Web of Science ®Google Scholar
• HumbertMMorrellNWArcherSLCellular and molecular pathobiology of pulmonary arterial hypertensionJ Am Coll Cardiol20044313S24S15194174
   PubMed Web of Science ®Google Scholar
• HumbertMSitbonOSimonneauGTreatment of pulmonary arterial hypertensionN Engl J Med200435114253615459304
   PubMed Web of Science ®Google Scholar
• JaisXGhofraniAHoeperMMBosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): a randomized, placebo-controlled trialAm J Resp Crit Care Med2007173A896
   Google Scholar
• JamiesonSWKapelanskiDPSakakibaraNPulmonary endarterectomy: experience and lessons learned in 1,500 casesAnn Thorac Surg20037614576414602267
   PubMed Web of Science ®Google Scholar
• JonesKHigenbottamTWallworkJPulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertensionChest19899678492507232
   PubMed Web of Science ®Google Scholar
• KatwaLCGuardaEWeberKTEndothelin receptors in cultured adult rat cardiac fibroblastsCardiovasc Res199327212598313418
   PubMed Web of Science ®Google Scholar
• KeoghAMMcNeilKDWlodarczykJQuality of life in pulmonary arterial hypertension: improved and maintained with bosentanJ Heart Lung Transplantation2007261817
   PubMed Web of Science ®Google Scholar
• KotlyarESyRKeoghAMBosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac diseaseCardiol Young2006162687416725066
   PubMed Web of Science ®Google Scholar
• LaneKBMachadoRDPauciuloMWHeterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH ConsortiumNat Genet20002681410973254
   PubMed Web of Science ®Google Scholar
• LevinEREndothelinsN Engl J Med1995333356637609754
   PubMed Web of Science ®Google Scholar
• LunzeKGilbertNMebusSFirst experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertensionEur J Clin Invest200636S332816919008
   PubMedGoogle Scholar
• McLaughlinVVOudizRJFrostARandomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertensionAm J Respir Crit Care Med200617412576316946127
   PubMed Web of Science ®Google Scholar
• McLaughlinVVSitbonOBadeschDBSurvival with first-line bosentan in patients with primary pulmonary hypertensionEur Respir J200525244915684287
   PubMed Web of Science ®Google Scholar
• MoserKMAugerWRFedulloPFChronic major-vessel thromboembolic pulmonary hypertensionCirculation1990811735432188751
   PubMed Web of Science ®Google Scholar
• MuskMChambersDLawrenceSBosentan improves WHO functional class, exercise capacity and RV size in inoperable chronic thromboembolic pulmonary hypertension (CTEPH)J Heart Lung Transplantation200625S77
   Web of Science ®Google Scholar
• NewmanJHWhellerLLaneKBMutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindredN Engl J Med20013453192411484688
   PubMed Web of Science ®Google Scholar
• NeylonCBAvdoninPVDilleyRJDifferent electrical responses to vasoactive agonists in morphologically distinct smooth muscle cell typesCirc Res199475733417522987
   PubMed Web of Science ®Google Scholar
• OlschewskiHSimonneauGGalieNAerosolized Iloprost Randomized Study Group: Inhaled iloprost for severe pulmonary hypertensionN Engl J Med2002347322912151469
   PubMed Web of Science ®Google Scholar
• PaulGAGibbsSRBoobisARBosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertensionBr J Clin Pharmacol2005601071215963102
   PubMed Web of Science ®Google Scholar
• ProvencherSSitbonOHumbertMLong-term outcome with first line bosentan therapy in idiopathic pulmonary arterial hypertensionEur Heart J2006275899516431875
   PubMed Web of Science ®Google Scholar
• RichSKaufmannELevyPSThe effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertensionN Engl J Med199232776811603139
   PubMed Web of Science ®Google Scholar
• RosenzweigEBIvyDDWilditzAEffects of long-term bosentan in children with pulmonary arterial hypertensionJ Am Coll Cardiol20054669770416098438
   PubMed Web of Science ®Google Scholar
• RubinLJACCP evidence-based clinical practice guidelines: Diagnosis and management of pulmonary arterial hypertensionChest20041261S92S
   PubMedGoogle Scholar
• RubinLJBadeschDBBarstRJBosentan therapy for pulmonary arterial hypertensionN Engl J Med200234689690311907289
   PubMed Web of Science ®Google Scholar
• RubinLJHoeperMMKlepetkoWCurrent and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responsesProc Am Thorac Soc20063601716963541
   PubMedGoogle Scholar
• RunoJRLoydJEPrimary pulmonary hypertensionLancet200336115334412737878
   PubMed Web of Science ®Google Scholar
• SimonneauGBarstRJGalieNContinuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trialAm J Respir Crit Care Med2002165800411897647
   PubMed Web of Science ®Google Scholar
• SimonneauGGalieNRubinLJClinical classification of pulmonary hypertensionJ Am Coll Cardiol2004435S12S15194173
   PubMed Web of Science ®Google Scholar
• SitbonOBadeschDBChannickRNEffects of the dual endothelin receptor antagonist Bosentan in patients with pulmonary arterial hypertension: A 1-year follow-up studyChest20031242475412853530
   PubMed Web of Science ®Google Scholar
• SitbonOGressinVSpeichRBosentan in pulmonary arterial hypertension associated with HIV infectionAm J Respir Crit Care Med200417012121715317666
   PubMed Web of Science ®Google Scholar
• SitbonOHumbertMNunesHLong-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survivalJ Am Coll Cardiol200240780812204511
   PubMed Web of Science ®Google Scholar
• SitbonOMcLaughlinVVBadeschDBSurvival in patients with class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of patients started on iv epoprostenolThorax20056010253016055621
   PubMed Web of Science ®Google Scholar
• SteinerMKPrestonIRKlingerJRConversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot studyChest200613014718017099026
   PubMed Web of Science ®Google Scholar
• StewartSMurphyNFMcMurrayJJVA population-based analysis of pulmonary arterial hypertension in Scotland (1996-2001)Eur Respir J2007in press
   Google Scholar
• StrangeCTreatment for Secondary Pulmonary HypertensionChest20051281897816236830
   PubMed Web of Science ®Google Scholar
• VoelkelNFTuderRMWeirEKRubinLRichSPathophysiology of primary pulmonary hypertension: From physiology to molecular mechanismsPrimary Pulmonary Hypertension1997New York, NYMarcel Deckerp83129
   Google Scholar
• WilliamsMHDasCHandlerCE2006Systemic sclerosis associated pulmonary hypertension: improved survival in the current eraHeart929263216339813
   PubMed Web of Science ®Google Scholar
• WlodarczykJHClelandLGKeoghAM2006Public funding of Bosentan for the treatment of pulmonary arterial hypertension in AustraliaPharmacoeconomics249031516942124
   PubMed Web of Science ®Google Scholar
• ZapolWMFalkeKJHurfordWEInhaling nitric oxide: a selective pulmonary vasodilator and bronchodilatorChest199410587S91S8131625
   PubMed Web of Science ®Google Scholar